Aduro BioTech (NASDAQ:ADRO) Shares Down 3.6%

Share on StockTwits

Shares of Aduro BioTech Inc (NASDAQ:ADRO) were down 3.6% during trading on Tuesday . The stock traded as low as $1.08 and last traded at $1.08, approximately 17,520 shares traded hands during mid-day trading. A decline of 98% from the average daily volume of 851,362 shares. The stock had previously closed at $1.12.

Several analysts recently commented on ADRO shares. ValuEngine upgraded Aduro BioTech from a “sell” rating to a “hold” rating in a report on Thursday, August 1st. Cowen reiterated a “buy” rating on shares of Aduro BioTech in a report on Friday, August 2nd. Five investment analysts have rated the stock with a hold rating and five have assigned a buy rating to the stock. The company currently has a consensus rating of “Buy” and a consensus price target of $8.01.

The stock has a market capitalization of $95.01 million, a P/E ratio of -0.92 and a beta of 1.48. The business has a fifty day simple moving average of $1.04 and a 200-day simple moving average of $1.76. The company has a debt-to-equity ratio of 0.39, a quick ratio of 7.26 and a current ratio of 7.26.

Aduro BioTech (NASDAQ:ADRO) last posted its quarterly earnings results on Thursday, November 7th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.23) by $0.03. The firm had revenue of $4.80 million for the quarter, compared to analysts’ expectations of $4.55 million. Aduro BioTech had a negative return on equity of 78.64% and a negative net margin of 544.94%. On average, sell-side analysts anticipate that Aduro BioTech Inc will post -0.95 earnings per share for the current year.

In other Aduro BioTech news, CEO Stephen T. Isaacs sold 31,098 shares of the stock in a transaction that occurred on Friday, September 13th. The stock was sold at an average price of $1.31, for a total transaction of $40,738.38. Following the transaction, the chief executive officer now directly owns 295,926 shares in the company, valued at approximately $387,663.06. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Insiders have sold a total of 52,185 shares of company stock worth $68,362 over the last 90 days. Company insiders own 5.20% of the company’s stock.

Institutional investors have recently bought and sold shares of the business. Wedbush Securities Inc. bought a new stake in shares of Aduro BioTech in the 3rd quarter worth approximately $39,000. UBS Asset Management Americas Inc. boosted its position in shares of Aduro BioTech by 106.9% during the second quarter. UBS Asset Management Americas Inc. now owns 55,233 shares of the biotechnology company’s stock valued at $85,000 after purchasing an additional 28,533 shares in the last quarter. Jane Street Group LLC bought a new stake in shares of Aduro BioTech during the second quarter valued at approximately $56,000. Morgan Stanley boosted its position in shares of Aduro BioTech by 138.8% during the second quarter. Morgan Stanley now owns 66,730 shares of the biotechnology company’s stock valued at $103,000 after purchasing an additional 38,782 shares in the last quarter. Finally, AQR Capital Management LLC boosted its position in shares of Aduro BioTech by 75.8% during the second quarter. AQR Capital Management LLC now owns 701,608 shares of the biotechnology company’s stock valued at $1,080,000 after purchasing an additional 302,573 shares in the last quarter. Hedge funds and other institutional investors own 41.55% of the company’s stock.

About Aduro BioTech (NASDAQ:ADRO)

Aduro BioTech, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies to harness the body's natural immune system for the treatment of patients with challenging diseases. The company is developing ADU-S100, which is in Phase I dose escalation and dose expansion clinical trial and Phase Ib dose escalation and dose expansion clinical trial in combination with spartalizumab to treat patients with advanced, metastatic treatment-refractory solid tumors; Phase I clinical trial in combination with ipilimumab for the treatment of relapsed and refractory melanoma; and Phase Ib/II clinical trial in combination with an approved anti-PD-1 antibody in patients with squamous cell carcinoma of the head and neck.

Featured Story: Diversification in Investing

Receive News & Ratings for Aduro BioTech Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aduro BioTech and related companies with MarketBeat.com's FREE daily email newsletter.

 


Latest News

Yu Darvish Receives Cortisone Shot for Elbow Impingement
Yu Darvish Receives Cortisone Shot for Elbow Impingement
Red Sox and Brandon Phillips Agree to Minor League Deal
Red Sox and Brandon Phillips Agree to Minor League Deal
Chris Sale Proves He is 2018 AL Cy Young Candidate
Chris Sale Proves He is 2018 AL Cy Young Candidate
Strong Results by Clint Frazier Could Keep Him with Yankees
Strong Results by Clint Frazier Could Keep Him with Yankees
Giants Closer Breaks Hand Punching Door Following Poor Outing
Giants Closer Breaks Hand Punching Door Following Poor Outing
Evan Longoria Out Six to Eight Weeks With Broken Hand
Evan Longoria Out Six to Eight Weeks With Broken Hand


 
© 2006-2019 BBNS.